Relation and healthcare investment firm Deerfield Management, a current investor, has launched a new research collaboration to advance therapeutic discovery projects for diseases of high unmet need.
Ikarovec Ltd and VectorBuilder entered into an exclusive worldwide option agreement for VectorBuilder’s novel AAV capsid technology to be used with Ikarovec’s gene therapy candidate IKAR-003.
Dark Blue Therapeutics, a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been acquired by Amgen.
Happy New Year to all our BIA members and collaborators. We hope that the break has provided an opportunity for a refresh, ready for a jam-packed 2026. Many of you will be heading to JPM – don't miss the UK reception.
Working closely with BIA’s FTAC and HMRC, FTI Consulting have devoted a great deal of time interpreting the new legislation for qualifying overseas expenditure and guidance.
